Search research articles
Contact Us
Filters
Showing results (61-70 of 86) with videos related to
Page
of 9
Sort By:
Journal of the National Cancer Institute
|
April 5, 2017
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
Chee Khoon Lee, Lucy Davies, Yi-Long Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2017
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S Ramalingam, James C-H Yang, Chee Khoon Lee, et al.
Neuro-Oncology Advances
|
May 31, 2021
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma
Mustafa Khasraw, Michael Weller, David Lorente, et al.
Gynecologic Oncology
|
November 23, 2016
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Roberto Sorio, Célia Roemer-Becuwe, Felix Hilpert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2026
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Jhanelle E Gray, Konstantin Laktionov, Sang-We Kim, et al.
Gynecologic Oncology
|
November 13, 2024
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer
Katherine Elizabeth Francis, Sandy Simon, Val Gebski, et al.
Future Oncology (London, England)
|
June 9, 2025
Navigating advanced lung cancer care, patient-physician alliance, cancer stigma, and psychosocial support in Asia-Pacific: perspectives from patients, caregivers, and physicians
Chee Khoon Lee, Xue Yang, Yasushi Goto, et al.
Nature Communications
|
February 28, 2024
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE
Lavinia Tan, Chris Brown, Antony Mersiades, et al.
NPJ Precision Oncology
|
September 9, 2024
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation
Subotheni Thavaneswaran, Frank Lin, John P Grady, et al.
JAMA Oncology
|
December 29, 2022
Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer
Kirsty W C Lee, Molly S C Li, Wanxia Gai, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 86) with videos related to
Sort By:
Page
of 9
Journal of the National Cancer Institute
|
April 5, 2017
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
Chee Khoon Lee, Lucy Davies, Yi-Long Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2017
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S Ramalingam, James C-H Yang, Chee Khoon Lee, et al.
Neuro-Oncology Advances
|
May 31, 2021
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma
Mustafa Khasraw, Michael Weller, David Lorente, et al.
Gynecologic Oncology
|
November 23, 2016
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Roberto Sorio, Célia Roemer-Becuwe, Felix Hilpert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2026
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Jhanelle E Gray, Konstantin Laktionov, Sang-We Kim, et al.
Gynecologic Oncology
|
November 13, 2024
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer
Katherine Elizabeth Francis, Sandy Simon, Val Gebski, et al.
Future Oncology (London, England)
|
June 9, 2025
Navigating advanced lung cancer care, patient-physician alliance, cancer stigma, and psychosocial support in Asia-Pacific: perspectives from patients, caregivers, and physicians
Chee Khoon Lee, Xue Yang, Yasushi Goto, et al.
Nature Communications
|
February 28, 2024
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE
Lavinia Tan, Chris Brown, Antony Mersiades, et al.
NPJ Precision Oncology
|
September 9, 2024
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation
Subotheni Thavaneswaran, Frank Lin, John P Grady, et al.
JAMA Oncology
|
December 29, 2022
Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer
Kirsty W C Lee, Molly S C Li, Wanxia Gai, et al.
Page
of 9